IAG Bio-Partnering Team to Attend BIO Spain in Seville

IAG Bio-Partnering Team to Attend BIO Spain in Seville

IAG Bio-Partnering Team to Attend BIO Spain in Seville

IAG lead Bio-Partnering Analyst, Dr. Diana Roettger will be attending BIO SPAIN 2018 in Seville, Spain, from September 25 – 27. IAG partners with biotechnology and pharmaceutical companies and supports clinical research programs with its scientific, operational and technological expertise. IAG’s Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.

The scope of discussions for this conference include:

– Development of clinical stage assets

– IP acquisition from the academic partners and biotech companies

– Investment partnerships

– Strategic collaborations

Given the increasing need for collaboration in therapy development, Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies. To find out more about IAG Bio-Partnering services or to schedule a meeting during BIO 2018 please send an email to contact@ia-grp.com

About BIO Spain 2018

BIOSPAIN is one of the largest biotech event with up to 3,000 one-to-one meetings and +800 participating companies providing an excellent networking opportunity for over 1800 delegates from 29 countries. To find out more about this conference click here.

About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com